New pharmaceutical applications for macromolecular binders

Journal of Controlled Release

Volumn 155, Issue 2, 2011, Pages 200-210

  Bertrand, Nicolas ^a   Gauthier, Marc A ^b   Bouvet, Céline ^a   Moreau, Pierre ^a   Petitjean, Anne ^c   Leroux, Jean Christophe ^a,b   Leblond, Jeanne ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b ETH ZURICH   (Switzerland)

^c QUEEN S UNIVERSITY   (Canada)

Author keywords

Chelators; Cyclodextrins; Nanomedicine; Polymeric binders; Polymeric drugs

Indexed keywords

BINDING PROPERTIES; BIOLOGICAL RESPONSE; CHELATORS; ILLUSTRATIVE EXAMPLES; LARGER SUBSTRATES; MACROMOLECULAR BINDERS; MACROMOLECULAR DRUGS; MULTIVALENT BINDING; NANOMEDICINES; PHARMACEUTICAL APPLICATIONS; POLYMERIC BINDER; POLYMERIC DRUGS;

BINDERS; BINDING ENERGY; CYCLODEXTRINS; DENDRIMERS; MEDICAL NANOTECHNOLOGY; OLIGOMERS; SUBSTRATES;

MACROMOLECULES;

COLESEVELAM; COLESTILAN; COLESTIPOL; COLESTYRAMINE; MACROGOL DERIVATIVE; MACROMOLAR BINDER; OLIGOMER; POLY(ETHYLENE GLYCOL) CAFFEINE CONJUGATE; POLYMER; PROTEIN; SEVELAMER; SUGAMMADEX; UNCLASSIFIED DRUG; AMITRIPTYLINE; ANTHRAX TOXIN; ANTIBIOTIC AGENT; APTAMER; BILE SALT; CHOLESTEROL; CHROMOSORB P; DENDRIMER; FIBRIN; IRON; L SELECTIN; MACROMOLECULAR BINDER; MISCELLANEOUS DRUGS AND AGENTS; PADGEM PROTEIN; PHOSPHATE; POLYSTYRENESULFONATE SODIUM; ROCURONIUM; SHIGA TOXIN; SYNSORB 90; TOLEVAMER; VANCOMYCIN; VIVAGEL;

BINDING AFFINITY; BINDING KINETICS; BIOLOGICAL ACTIVITY; CELLULAR DISTRIBUTION; CONFERENCE PAPER; DETOXIFICATION; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; ELECTROLYTE DISTURBANCE; HALF LIFE TIME; NEUROMUSCULAR BLOCKING; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; VIRUS ATTACHMENT; ANTIBACTERIAL ACTIVITY; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; DRUG EFFICACY; ESCHERICHIA COLI; EUKARYOTE; EUKARYOTIC CELL; GRAM POSITIVE BACTERIUM; HERPES SIMPLEX; HOSPITAL INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERKALEMIA; INFLUENZA; MACROMOLECULE; MOLECULAR INTERACTION; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL CHEMISTRY; STARFISH;

BIOPHARMACEUTICS; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; DRUG DESIGN; MACROMOLECULAR SUBSTANCES;

EID: 80054098915     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2011.04.027     Document Type: Conference Paper

References (118)

1. R.A. Petros, and J.M. DeSimone Strategies in the design of nanoparticles for therapeutic applications Nat. Rev. Drug Discov. 9 2010 615 627
2. D. Peer, J.M. Karp, S. Hong, O.C. Farokhzad, R. Margalit, and R. Langer Nanocarriers as an emerging platform for cancer therapy Nat. Nanotechnol. 2 2007 751 760 (Pubitemid 350223348)
3. R. Duncan Polymer conjugates as anticancer nanomedicines Nat. Rev. Cancer 6 2006 688 701 (Pubitemid 44286001)
4. R. Duncan The dawning era of polymer therapeutics Nat. Rev. Drug Discov. 2 2003 347 360 (Pubitemid 37361705)
5. K.L. Kiick Polymer therapeutics Science 317 2007 1182 1183
6. J. Rao, J. Lahiri, L. Isaacs, R.M. Weis, and G.M. Whitesides A trivalent system from Vancomycin-D-Ala-D-Ala with higher affinity than avidin-biotin Science 280 1998 708 711 (Pubitemid 28243338)
7. M. Mammen, S.-K. Choi, and G.M. Whitesides Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors Angew. Chem. Int. Ed. Engl. 37 1998 2754 2794 (Pubitemid 29008561)
8. F. van de Manakker, T. Vermonden, C.F. van Nostrum, and W.E. Hennink Cyclodextrin-based polymeric materials: synthesis, properties, and pharmaceutical/biomedical applications Biomacromolecules 10 2009 3157 3175
9. J.W. Zhou, and H. Ritter Cyclodextrin functionalized polymers as drug delivery systems Polym. Chem. 1 2010 1552 1559
10. J.E. Gestwicki, and L.L. Kiessling Inter-receptor communication through arrays of bacterial chemoreceptors Nature 415 2002 81 82
11. X. Gong, D. Dubois, D. Miller, and B. Shur Activation of a G protein complex by aggregation of beta-1,4-galactosyltransferase on the surface of sperm Science 269 1995 1718 1721
12. P.K. Dhal, S.C. Polomoscanik, L.Z. Avila, S.R. Holmes-Farley, and R.J. Miller Functional polymers as therapeutic agents: concept to market place Adv. Drug Deliv. Rev. 61 2009 1121 1130
13. C.J. Hawker, and K.L. Wooley The convergence of synthetic organic and polymer chemistries Science 309 2005 1200 1205 (Pubitemid 41170906)
14. A. Bossi, F. Bonini, A.P.F. Turner, and S.A. Piletsky Molecularly imprinted polymers for the recognition of proteins: The state of the art Biosens. Bioelectron. 22 2007 1131 1137 (Pubitemid 44894899)
15. N.M. Bergmann, and N.A. Peppas Molecularly imprinted polymers with specific recognition for macromolecules and proteins Prog. Polym. Sci. 33 2008 271 288 (Pubitemid 351625301)
16. M. Watson, K.C. Abbott, and C.M. Yuan Damned if you do, damned if you don't: potassium binding resins in hyperkalemia Clin. J. Am. Soc. Nephrol. 5 2010 1723 1726
17. P. Biggar, and M. Ketteler Sevelamer carbonate for the treatment of hyperphosphatemia in patients with kidney failure (CKD III-V) Expert Opin. Pharmacother. 11 2010 2739 2750
18. N.A.A. Rossi, I. Mustafa, J.K. Jackson, H.M. Burt, S.A. Horte, M.D. Scott, and J.N. Kizhakkedathu In vitro chelating, cytotoxicity, and blood compatibility of degradable poly(ethylene glycol)-based macromolecular iron chelators Biomaterials 30 2009 638 648
19. J. Lim, V.J. Venditto, and E.E. Simanek Synthesis and characterization of a triazine dendrimer that sequesters iron(III) using 12 desferrioxamine B groups Bioorg. Med. Chem. 18 2010 5749 5753
20. T. Zhou, X.L. Kong, Z.D. Liu, D.Y. Liu, and R.C. Hider Synthesis and iron(III)-chelating properties of novel 3-hydroxypyridin-4-one hexadentate ligand-containing copolymers Biomacromolecules 9 2008 1372 1380 (Pubitemid 351757114)
21. L. Abi-Mosleh, R.E. Infante, A. Radhakrishnan, J.L. Goldstein, and M.S. Brown Cyclodextrin overcomes deficient lysosome-to-endoplasmic reticulum transport of cholesterol in Niemann-Pick type C cells Proc. Natl. Acad. Sci. USA 106 2009 19316 19321
22. G.J. Tarver, S.J.A. Grove, K. Buchanan, A. Bom, A. Cooke, S.J. Rutherford, and M.-Q. Zhang 2-O-substituted cyclodextrins as reversal agents for the neuromuscular blocker rocuronium bromide Bioorg. Med. Chem. 10 2002 1819 1827 (Pubitemid 34286374)
23. S. Oney, R.T.S. Lam, K.M. Bompiani, C.M. Blake, G. Quick, J.D. Heidel, J.Y.-C. Liu, B.C. Mack, M.E. Davis, K.W. Leong, and B.A. Sullenger Development of universal antidotes to control aptamer activity Nat. Med. 15 2009 1224 1228
24. D.-W. Lee, J. Flint, T. Morey, D. Dennis, R. Partch, and R. Baney Aromatic-aromatic interaction of amitriptyline: implication of overdosed drug detoxification J. Pharm. Sci. 94 2005 373 381 (Pubitemid 40293333)
25. K. Weiss Toxin-binding treatment for Clostridium difficile: a review including reports of studies with tolevamer Int. J. Antimicrob. Agents 33 2009 4 7
26. M. Pinier, E.F. Verdu, M. Nasser-Eddine, C.S. David, A. Vézina, N. Rivard, and J.C. Leroux Polymeric binders suppress gliadin-induced toxicity in the intestinal epithelium Gastroenterology 136 2009 288 298
27. G.L. Mulvey, P. Marcato, P.I. Kitov, J. Sadowska, D.R. Bundle, and G.D. Armstrong Assessment in mice of the therapeutic potential of tailored, multivalent shiga toxin carbohydrate ligands J. Infect. Dis. 187 2003 640 649 (Pubitemid 36250028)
28. M. Watanabe, K. Matsuoka, E. Kita, K. Igai, N. Higashi, A. Miyagawa, T. Watanabe, R. Yanoshita, Y. Samejima, D. Terunuma, Y. Natori, and K. Nishikawa Oral therapeutic agents with highly clustered globotriose for treatment of shiga toxigenic Escherichia coli infections J. Infect. Dis. 189 2004 360 368 (Pubitemid 38210571)
29. P.I. Kitov, G.L. Mulvey, T.P. Griener, T. Lipinski, D. Solomon, E. Paszkiewicz, J.M. Jacobson, J.M. Sadowska, M. Suzuki, K.-i. Yamamura, G.D. Armstrong, and D.R. Bundle In vivo supramolecular templating enhances the activity of multivalent ligands: a potential therapeutic against the Escherichia coli O157 AB5 toxins Proc. Natl. Acad. Sci. USA 105 2008 16837 16842
30. M. Mourez, R.S. Kane, J. Mogridge, S. Metallo, P. Deschatelets, B.R. Sellman, G.M. Whitesides, and R.J. Collier Designing a polyvalent inhibitor of anthrax toxin Nat. Biotechnol. 19 2001 958 961 (Pubitemid 32947575)
31. K.V. Gujraty, A. Joshi, A. Saraph, V. Poon, J. Mogridge, and R.S. Kane Synthesis of polyvalent inhibitors of controlled molecular weight: structure-activity relationship for inhibitors of anthrax toxin Biomacromolecules 7 2006 2082 2085 (Pubitemid 44103346)
32. A. Joshi, A. Saraph, V. Poon, J. Mogridge, and R.S. Kane Synthesis of potent inhibitors of anthrax toxin based on poly-L-glutamic acid Bioconjug. Chem. 17 2006 1265 1269 (Pubitemid 44455336)
33. B.F.L. Lai, Y. Zou, D.E. Brooks, and J.N. Kizhakkedathu The influence of poly-N-[(2,2-dimethyl-1,3-dioxolane)methyl]acrylamide on fibrin polymerization, cross-linking and clot structure Biomaterials 31 2010 5749 5758
34. D. Tyssen, S.A. Henderson, A. Johnson, J. Sterjovski, K. Moore, J. La, M. Zanin, S. Sonza, P. Karellas, M.P. Giannis, G. Krippner, S. Wesselingh, T. McCarthy, P.R. Gorry, P.A. Ramsland, R. Cone, J.R. Paull, G.R. Lewis, and G. Tachedjian Structure activity relationship of dendrimer microbicides with dual action antiviral activity PLoS One 5 2010 e12309
35. T. Honda, S. Yoshida, M. Arai, T. Masuda, and M. Yamashita Synthesis and anti-influenza evaluation of polyvalent sialidase inhibitors bearing 4-guanidino-Neu5Ac2en derivatives Bioorg. Med. Chem. Lett. 12 2002 1929 1932 (Pubitemid 34756451)
36. A.S. Gambaryan, E.Y. Boravleva, T.Y. Matrosovich, M.N. Matrosovich, H.D. Klenk, E.V. Moiseeva, A.B. Tuzikov, A.A. Chinarev, G.V. Pazynina, and N.V. Bovin Polymer-bound 6′ sialyl-N-acetyllactosamine protects mice infected by influenza virus Antiviral Res. 68 2005 116 123 (Pubitemid 41612455)
37. US-NIH Dose ranging study of SPL7013 gel for treatment of bacterial vaginosis (BV) http://clinicaltrials.gov/ [Last accessed on: 2011-02-07]
38. V.M. Krishnamurthy, L.J. Quinton, L.A. Estroff, S.J. Metallo, J.M. Isaacs, J.P. Mizgerd, and G.M. Whitesides Promotion of opsonization by antibodies and phagocytosis of Gram-positive bacteria by a bifunctional polyacrylamide Biomaterials 27 2006 3663 3674
39. J. Li, S. Zacharek, X. Chen, J. Wang, W. Zhang, A. Janczuk, and P.G. Wang Bacteria targeted by human natural antibodies using α-Gal conjugated receptor-specific glycopolymers Bioorg. Med. Chem. 7 1999 1549 1558 (Pubitemid 29347121)
40. J. Dernedde, A. Rausch, M. Weinhart, S. Enders, R. Tauber, K. Licha, M. Schirner, U. Zügel, A. von Bonin, and R. Haag Dendritic polyglycerol sulfates as multivalent inhibitors of inflammation Proc. Natl. Acad. Sci. USA 107 2010 19679 19684
41. K. Wu, J. Liu, R.N. Johnson, J. Yang, and J. Kopeček Drug-free macromolecular therapeutics: induction of apoptosis by coiled-coil-mediated cross-linking of antigens on the cell surface Angew. Chem. Int. Ed. Engl. 49 2010 1451 1455
42. H.-J. Schneider Binding mechanisms in supramolecular complexes Angew. Chem. Int. Ed. Engl. 48 2009 3924 3977
43. A. Bellasi, L. Kooienga, and G.A. Block Phosphate binders: new products and challenges Hemodial. Int. 10 2006 225 234 (Pubitemid 43923204)
44. P. Dhal, S. Holmes-Farley, C. Huval, and T. Jozefiak R. Satchi-Fainaro, R. Duncan, Polymer Therapeutics I vol. 192 2006 Springer Berlin / Heidelberg 9 58
45. ATSDR CERCLA priority list of harzardous substances http://www.atsdr.cdc. gov/ 2007 [Last accessed on: 2011-01-27]
46. O. Barbier, G. Jacquillet, M. Tauc, M. Cougnon, and P. Poujeol Effect of heavy metals on, and handling by, the kidney Nephron Physiol. 99 2005 105 110
47. W.C. Prozialeck, J.R. Edwards, D.W. Nebert, J.M. Woods, A. Barchowsky, and W.D. Atchison The vascular system as a target of metal toxicity Toxicol. Sci. 102 2008 207 218 (Pubitemid 351404893)
48. O. Andersen Principles and recent developments in chelation treatment of metal intoxication Chem. Rev. 99 1999 2683 2710
49. S.J.S. Flora, M. Mittal, and A. Mehta Heavy metal induced oxidative stress and its possible reversal by chelation therapy Indian J. Med. Res. 128 2008 501 523
50. G.F. Nordberg Chelating agents and cadmium toxicity: problems and prospects Environ. Health Perspect. 54 1984 213 218 (Pubitemid 14094123)
51. A. Bernard Cadmium and its adverse effects on human health Indian J. Med. Res. 128 2008 557 564
52. T. Yamaoka Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice J. Pharm. Sci. 83 1994 601 606 (Pubitemid 24222392)
53. S. Nafisi, S.A. Sadjadi, S.S. Zadeh, and M. Damerchelli Interaction of metal ions with caffeine and theophylline: stability and structural features J. Biomol. Struct. Dyn. 21 2003 289 296
54. N. Bertrand, J.G. Fleischer, K.M. Wasan, and J.C. Leroux Pharmacokinetics and biodistribution of N-isopropylacrylamide copolymers for the design of pH-sensitive liposomes Biomaterials 30 2009 2598 2605
55. K. Tziomalos, V.G. Athyros, and D.P. Mikhailidis Colesevelam improves glycemic control and lipid management in inadequately controlled type 2 diabetes mellitus Nat. Clin. Pract. Endocrinol. Metab. 5 2009 16 17
56. B. Staels A review of bile acid sequestrants: potential mechanism(s) for glucose-lowering effects in type 2 diabetes mellitus Postgrad. Med. 121 2009 25 30
57. A. Bom, M. Bradley, K. Cameron, J.K. Clark, J. van Egmond, H. Feilden, E.J. MacLean, A.W. Muir, R. Palin, D.C. Rees, and M.-Q. Zhang A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host Angew. Chem. Int. Ed. Engl. 41 2002 265 270 (Pubitemid 34126377)
58. F. Gijsenbergh, S. Ramael, N. Houwing, and T. van Iersel First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide Anesthesiology 103 2005 695 703 (Pubitemid 41415517)
59. L. Booij, J. van Egmond, J. Driessen, and H. de Boer In vivo animal studies with sugammadex Anaesthesia 64 Suppl. 1 2009 38 44
60. I.F. Sorgenfrei, K. Norrild, P.B. Larsen, J. Stensballe, D. Ostengard, M.E. Prins, and J. Viby-Morgensen Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex Anesthesiology 104 2006 667 674
61. M. Shields, M. Giovanelli, R. Mirakhur, I. Moppett, J. Adams, and Y. Hermens Org 25969 (sugammadex), a selective relaxant binding agent for antagonism of prolonged rocuronium-induced neuromuscular block Br. J. Anaesth. 96 2006 36 43 (Pubitemid 43124528)
62. M. Naguib Sugammadex: another milestone in clinical neuromuscular pharmacology Anesth. Analg. 104 2007 575 581 (Pubitemid 46331731)
63. A. Lenz, G. Hill, and P.F. White Emergency use of sugammadex after failure of standard reversal drugs Anesth. Analg. 104 2007 585 586
64. B. Liu, S.D. Turley, D.K. Burns, A.M. Miller, J.J. Repa, and J.M. Dietschy Reversal of defective lysosomal transport in NPC disease ameliorates liver dysfunction and neurodegeneration in the npc1-/- mouse Proc. Natl. Acad. Sci. USA 106 2009 2377 2382
65. A.I. Rosenbaum, G. Zhang, J.D. Warren, and F.R. Maxfield Endocytosis of β-cyclodextrins is responsible for cholesterol reduction in Niemann-Pick type C mutant cells Proc. Natl. Acad. Sci. USA 107 2010 5477 5482
66. T. Hermann, and D.J. Patel Biochemistry - Adaptive recognition by nucleic acid aptamers Science 287 2000 820 825 (Pubitemid 30084318)
67. S. Oney, S.M. Nimjee, J. Layzer, N. Que-Gewirth, D. Ginsburg, R.C. Becker, G. Arepally, and B.A. Sullenger Antidote-controlled platelet inhibition targeting von Willebrand factor with aptamers Oligonucleotides 17 2007 265 274 (Pubitemid 47463359)
68. C.P. Rusconi, E. Scardino, J. Layzer, G.A. Pitoc, T.L. Ortel, D. Monroe, and B.A. Sullenger RNA aptamers as reversible antagonists of coagulation factor IXa Nature 419 2002 90 94 (Pubitemid 34987876)
69. C.K. Dyke, S.R. Steinhubl, N.S. Kleiman, R.O. Cannon, L.G. Aberle, M. Lin, S.K. Myles, C. Melloni, R.A. Harrington, J.H. Alexander, R.C. Becker, and C.P. Rusconi First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity Circulation 114 2006 2490 2497 (Pubitemid 44901522)
70. C.P. Rusconi, J.D. Roberts, G.A. Pitoc, S.M. Nimjee, R.R. White, G. Quick, E. Scardino, W.P. Fay, and B.A. Sullenger Antidote-mediated control of an anticoagulant aptamer in vivo Nat. Biotechnol. 22 2004 1423 1428 (Pubitemid 39482862)
71. M.E. Kleinman, K. Yamada, A. Takeda, V. Chandrasekaran, M. Nozaki, J.Z. Baffi, R.J.C. Albuquerque, S. Yamasaki, M. Itaya, Y. Pan, B. Appukuttan, D. Gibbs, Z. Yang, K. Kariko, B.K. Ambati, T.A. Wilgus, L.A. DiPietro, E. Sakurai, K. Zhang, J.R. Smith, E.W. Taylor, and J. Ambati Sequence- and target-independent angiogenesis suppression by siRNA via TLR3 Nature 452 2008 591 597 (Pubitemid 351483358)
72. W. Braunlin, Q. Xu, P. Hook, R. Fitzpatrick, J.D. Klinger, R. Burrier, and C.B. Kurtz Toxin binding of tolevamer, a polyanionic drug that protects against antibiotic-associated diarrhea Biophys. J. 87 2004 534 539 (Pubitemid 38880106)
73. L.D. Heerze, M.A. Kelm, J.A. Talbot, and G.D. Armstrong Oligosaccharide sequences attached to an inert support (SYNSORB) as potential therapy for antibiotic-associated diarrhea and pseudomembranous colitis J. Infect. Dis. 169 1994 1291 1296 (Pubitemid 24164593)
74. J.E. Gestwicki, C.W. Cairo, L.E. Strong, K.A. Oetjen, and L.L. Kiessling Influencing receptor-ligand binding mechanisms with multivalent ligand architecture J. Am. Chem. Soc. 124 2002 14922 14933 (Pubitemid 36014100)
75. P.I. Kitov, J.M. Sadowska, G. Mulvey, G.D. Armstrong, H. Ling, N.S. Pannu, R.J. Read, and D.R. Bundle Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands Nature 403 2000 669 672 (Pubitemid 30104009)
76. J. Peppe, A. Porzio, and D.M. Davidson A new formulation of tolevamer, a novel nonantibiotic polymer, is safe and well-tolerated in healthy volunteers: a randomized phase I trial Br. J. Clin. Pharmacol. 66 2008 102 109 (Pubitemid 351822150)
77. C. TeWen, B.O. Andrew, and G.B. John Anion-exchange resins in antibiotics-associated colitis Lancet 312 1978 258 259
78. E.J. Burbige, and F.D. Milligan Pseudomembranous colitis J. Am. Med. Assoc. 231 1975 1157 1158
79. N.S. Taylor, and J.G. Bartlett Binding of Clostridium difficile cytotoxin and vancomycin by anion-exchange resins J. Infect. Dis. 141 1980 92 97 (Pubitemid 10133840)
80. C.B. Kurtz, E.P. Cannon, A. Brezzani, M. Pitruzzello, C. Dinardo, E. Rinard, D.W.K. Acheson, R. Fitzpatrick, P. Kelly, K. Shackett, A.T. Papoulis, P.J. Goddard, R.H. Barker Jr., G.P. Palace, and J.D. Klinger GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis Antimicrob. Agents Chemother. 45 2001 2340 2347 (Pubitemid 32664476)
81. R.H. Barker Jr., R. Dagher, D.M. Davidson, and J.K. Marquis Tolevamer, a novel toxin-binding polymer: overview of preclinical pharmacology and physicochemical properties Aliment. Pharmacol. Ther. 24 2006 10
82. T.J. Louie, J. Peppe, C.K. Watt, D. Johnson, R. Mohammed, G. Dow, K. Weiss, S. Simon, J.F. John, G. Garber, S.-C. Taber, D.M. Davidson, and t.T.S.I. Group Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea Clin. Infect. Dis. 43 2006 411 420 (Pubitemid 44157147)
83. K.D. Tucker, and T.D. Wilkins Toxin A of Clostridium difficile binds to the human carbohydrate antigens I, X, and Y Infect. Immun. 59 1991 73 78
84. I. Castagliuolo, J.T. LaMont, B. Qiu, S.T. Nikulasson, and C. Pothoulakis A receptor decoy inhibits the enterotoxic effects of Clostridium difficile toxin A in rat ileum Gastroenterology 111 1996 433 438 (Pubitemid 26256732)
85. S.A. Kuehne, S.T. Cartman, J.T. Heap, M.L. Kelly, A. Cockayne, and N.P. Minton The role of toxin A and toxin B in Clostridium difficile infection Nature 467 2010 711 713
86. D. Lyras, J.R. O'Connor, P.M. Howarth, S.P. Sambol, G.P. Carter, T. Phumoonna, R. Poon, V. Adams, G. Vedantam, S. Johnson, D.N. Gerding, and J.I. Rood Toxin B is essential for virulence of Clostridium difficile Nature 458 2009 1176 1179
87. G.J. Tack, W.H.M. Verbeek, M.W.J. Schreurs, and C.J.J. Mulder The spectrum of celiac disease: epidemiology, clinical aspects and treatment Nat. Rev. Gastroenterol. Hepatol. 7 2010 204 213
88. L.M. Sollid Coeliac disease: dissecting a complex inflammatory disorder Nat. Rev. Immunol. 2 2002 647 655 (Pubitemid 37328722)
89. M. Pinier, G. Fuhrmann, E. Verdu, and J.-C. Leroux Prevention measures and exploratory pharmacological treatments of celiac disease Am. J. Gastroenterol. 105 2010 2551 2561
90. J. Gass, M.T. Bethune, M. Siegel, A. Spencer, and C. Khosla Combination enzyme therapy for gastric digestion of dietary gluten in patients with celiac sprue Gastroenterology 133 2007 472 480 (Pubitemid 47187353)
91. B.M. Paterson, K.M. Lammers, M.C. Arrieta, A. Fasano, and J.B. Meddings The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study Aliment. Pharmacol. Ther. 26 2007 757 766 (Pubitemid 47246202)
92. R.E. Watts, M. Siegel, and C. Khosla Structure-activity relationship analysis of the selective inhibition of transglutaminase 2 by dihydroisoxazoles J. Med. Chem. 49 2006 7493 7501 (Pubitemid 44913408)
93. J. Xia, M. Siegel, E. Bergseng, L.M. Sollid, and C. Khosla Inhibition of HLA-DQ2-mediated antigen presentation by analogues of a high affinity 33-residue peptide from alpha2-gliadin J. Am. Chem. Soc. 128 2006 1859 1867 (Pubitemid 43277324)
94. L.K. Catherine, D. James, C. Zhenjun, P.A. Robert, and M. James Immune tolerance induced by peptide immunotherapy in an HLA DQ2-dependent mouse model of gluten immunity Gastroenterology 136 2009 A-57
95. L. Liang, M. Pinier, J.-C. Leroux, and M. Subirade Interaction of α-gliadin with poly(HEMA-co-SS): structural characterization and biological implication Biopolymers 91 2009 169 178
96. L. Liang, M. Pinier, J.-C. Leroux, and M. Subirade Interaction of α-gliadin with polyanions: design considerations for sequestrants used in supportive treatment of celiac disease Biopolymers 93 2010 418 428
97. S.-K. Choi, M. Mammen, and G.M. Whitesides Generation and in situ evaluation of libraries of poly(acrylic acid) presenting sialosides as side chains as polyvalent inhibitors of influenza-mediated hemagglutination J. Am. Chem. Soc. 119 1997 4103 4111 (Pubitemid 27239958)
98. E. Gong, B. Matthews, T. McCarthy, J. Chu, G. Holan, J. Raff, and S. Sacks Evaluation of dendrimer SPL7013, a lead microbicide candidate against herpes simplex viruses Antiviral Res. 68 2005 139 146 (Pubitemid 41612458)
99. D. Bernstein, L.R. Stanberry, S. Sacks, N. Ayisi, Y. Gong, J. Ireland, R. Mumper, G. Holan, B. Matthews, T. McCarthy, and N. Bourne Evaluation of unformulated and formulated dendrimer-based microbicide candidates in mouse and guinea pig models of genital herpes Antimicrob. Agents Chemother. 47 2003 3784 3788 (Pubitemid 37484989)
100. Y. Ohta, J.-B. Lee, K. Hayashi, and T. Hayashi Isolation of sulfated galactan from Codium fragile and its antiviral effect Biol. Pharm. Bull. 32 2009 892 898
101. 89.6P in macaques AIDS Res. Hum. Retroviruses 21 2005 207 213 (Pubitemid 40478228)
102. J.I. Jay, B.E. Lai, D.G. Myszka, A. Mahalingam, K. Langheinrich, D.F. Katz, and P.F. Kiser Multivalent benzoboroxole functionalized polymers as gp120 glycan targeted microbicide entry inhibitors Mol. Pharm. 7 2009 116 129
103. G.B. Sigal, M. Mammen, G. Dahmann, and G.M. Whitesides Polyacrylamides bearing pendant α-sialoside groups strongly inhibit agglutination of erythrocytes by influenza virus: the strong inhibition reflects enhanced binding through cooperative polyvalent interactions J. Am. Chem. Soc. 118 1996 3789 3800 (Pubitemid 26168538)
104. R. Rupp, S.L. Rosenthal, and L.R. Stanberry VivaGel™ (SPL7013): A candidate dendrimer-microbicide for the prevention of HIV and HSV infection Int. J. Med. 2 2007 561 566
105. J. O'Loughlin, I.Y. Millwood, H.M. McDonald, C.F. Price, J.M. Kaldor, and J.R.A. Paull Safety, tolerability, and pharmacokinetics of SPL7013 gel (VivaGel®): a dose ranging, phase I study Sex. Transm. Dis. 37 2010 100 104
106. M.Y. Chen, I.Y. Millwood, H. Wand, M. Poynten, M. Law, J.M. Kaldor, S. Wesselingh, C.F. Price, L.J. Clark, J.R.A. Paull, and C.K. Fairley A randomized controlled trial of the safety of candidate microbicide SPL7013 gel when applied to the penis J. Acquir. Immune Defic. Syndr. 50 2009 375 380
107. M. Zasloff Antimicrobial peptides of multicellular organisms Nature 415 2002 389 395 (Pubitemid 34100944)
108. M. Werthen, M. Davoudi, A. Sonesson, D. Nitsche, M. Mörgelin, K. Blom, and A. Schmidtchen Pseudomonas aeruginosa-induced infection and degradation of human wound fluid and skin proteins ex vivo are eradicated by a synthetic cationic polymer J. Antimicrob. Chemother. 54 2004 772 779 (Pubitemid 39386730)
109. J.H. Jeong, Y.S. Byoun, and Y.S. Lee Poly(styrene-alt-maleic anhydride)-4-aminophenol conjugate: synthesis and antibacterial activity React. Funct. Polym. 50 2002 257 263
110. L. Qu, L. Gu, H. Li, S. Taylor, T. Elkin, P.G. Luo, T.-R.J. Tzeng, X. Jiang, R.A. Latour, F. Stutzenberger, A. Williams, and Y.-P. Sun Galactosylated polymeric nanoparticles: synthesis and adhesion interactions with Escherichia Coli J. Biomed. Nanotechnol. 1 2005 61 67
111. M.D. Disney, J. Zheng, T.M. Swager, and P.H. Seeberger Detection of bacteria with carbohydrate-functionalized fluorescent polymers J. Am. Chem. Soc. 126 2004 13343 13346 (Pubitemid 39382762)
112. W. Yang, C.-Y. Pan, M.-D. Luo, and H.-B. Zhang Fluorescent mannose-functionalized hyperbranched poly(amido amine)s: synthesis and interaction with E. Coli Biomacromolecules 11 2010 1840 1846
113. M.K. Müller, and L. Brunsweld A supramolecular polymer as a self-assembling polyvalent scaffold Angew. Chem. Int. Ed. Engl. 48 2009 2921 2924
114. E.B. Puffer, J.K. Pontrello, J.J. Hollenbeck, J.A. Kink, and L.L. Kiessling Activating B cell signaling with defined multivalent ligands ACS Chem. Biol. 2 2007 252 262 (Pubitemid 47629213)
115. H. Ulbrich, E.E. Eriksson, and L. Lindbom Leukocyte and endothelial cell adhesion molecules as targets for therapeutic interventions in inflammatory disease Trends Pharmacol. Sci. 24 2003 640 647 (Pubitemid 37494786)
116. J.C. Leroux Injectable nanocarriers for biodetoxification Nat. Nanotechnol. 2 2007 679 684
117. N. Bertrand, C. Bouvet, P. Moreau, and J.C. Leroux Transmembrane pH-gradient liposomes to treat cardiovascular drug intoxication ACS Nano 4 2010 7552 7558
118. R. Gaspar, and R. Duncan Polymeric carriers: preclinical safety and the regulatory implications for design and development of polymer therapeutics Adv. Drug Deliv. Rev. 61 2009 1220 1231